Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
Shots:
- The CHMP has granted positive opinion to Keytruda + pemetrexed & Pt-based CT as a 1L treatment of adults with unresectable non-epithelioid MPM, with the EC’s decision anticipated in Q4’24. The regimen was approved across the US in Sep 2024 for the same
- The opinion was based on the P-II/III (IND.227/KEYNOTE-483) study assessing Keytruda + CT vs CT alone, showing improved OS
- Study depicted a reduction in the death risk by 21%, with mOS of 17.3 vs 16.1mos., significantly improved PFS, with mPFS of 7.1mos. in both the arms and ORR of 52% vs 29%
Ref: Merck | Image: Merck
Related News:- Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
